Erythropoiesis Stimulating Agents
Erythropoiesis stimulating agents approaches to modulate activity
... approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of ...for erythropoiesis stimulating agents with longer half-lives that ...
14
Regulation of platelet count by erythropoiesis-stimulating agents – iron axis in hemodialysis patients
... Abstract: Higher doses of erythropoiesis-stimulating agents (ESAs) contribute to atherothrombotic cardiovascular disease in hemodialysis (HD) patients. Thrombocytosis is asso- ciated with increased ...
8
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome
... Sweden). Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic ...
17
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
... Abstract: Chemotherapy induced anemia (CIA) is a frequent complication of anticancer treatment, but often remains untreated. The main presenting symptom of CIA is fatigue, and this can have profound implications upon ...
8
Dipeptidyl peptidase 4 inhibitor linagliptin can decrease the dosage of erythropoiesis-stimulating agents in patients on hemodialysis
... Background: Dipeptidyl peptidase 4 (DPP4) inhibitors are very useful for the treatment of type 2 diabetes, especially to patients undergoing hemodialysis (HD). The main action of DPP4 inhibitors is to increase the ...
5
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
... Clinical trials in patients with chronic kidney disease (CKD) have demonstrated that attempting to achieve a higher hemoglobin with erythropoiesis-stimulating agents (ESA) leads to adverse ...
10
Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
... Background: Chemotherapy-induced anaemia is a common and significant complication of chemotherapy treatment. Blood transfusion and administration of Erythropoiesis-Stimulating Agents (ESAs) either ...
7
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
... ESAs: Erythropoiesis- stimulating agents; GFR: Glomerular filtration rate; Hb: Hemoglobin; ICD9-CM code: International Classification of Disease, 9th revision, clinical modification code; ID: Index ...
11
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
... Background: Erythropoiesis stimulating agents (ESAs) were proposed to enhance survival of renal tissues through direct effects via activation of EPO receptors on renal cells resulting in reduced cell ...
16
Erythropoiesis Stimulating Agents (ESAs) in the Treatment of Cardio Renal Syndrome Anaemia
... FDA recommendations refers not only to ESRD pa- tients but also to patients with cardio-renal syndrome anaemia especially type 2 and 4 so it is wise to accept these recommendations in clinical practice when we treat with ...
6
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
... Initially, the optimal degree of anemia correction in patients with chronic kidney disease by erythropoiesis-stimulating agents (ESAs) relied mainly on the results of observational studies. Many of ...
8
Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model
... (an erythropoiesis-stimulating agent [ESA]) to stimulate red blood cell production, as well as intravenous (IV) iron, which is a key component of this ...
9
Relationship between variations in time-dependent response to erythropoiesis-stimulating agents and mortality in hemodialysis patients: a single-center study
... kidney. Erythropoiesis-stimulating agent (ESA) therapy has resulted in substantial health benefits for ESRD patients, including improved quality of life, a reduced need for blood transfusion, and greater ...
8
Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
... A meta-analysis showed a 1.7-fold increased risk of a combination of venous and arterial thrombotic events in ESA-treated patients, mainly with solid tumors, compared with cancer pati[r] ...
10
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
... these agents, should be adequately powered, double-blind placebo-controlled, and of suffi- cient duration to assess the advantages and disadvan- tages of the ...
8
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C E DOSE) trial protocol
... Randomized clinical studies have consistently shown that Hb targets of 12.0-13.5 g/dL achieved with ESA cause an increase in adverse vascular events compared to Hb levels of 10-12 g/dL achieved with the same ...
7
Effect of long-acting erythropoiesis-stimulating agents on hemoglobin levels at the initiation of dialysis
... Using the study protocol, clinical information was re- corded for all patients at each nephrology unit immedi- ately prior to their first HD session. Information was also collected on the use of oral medications and ESA ...
10
Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
... Four patients (4.2%) in the bio- similar epoetin alfa group and four (8%) in the darbepoetin group required a red blood cell transfusion during the period of ESA treatment.. No deat[r] ...
6
Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure
... therapeutic agents like darbepoetin alpha (DPO) and recently approved once a month agent, methoxy polyethylene glycol-epoetin beta, called Erythropoiesis Stimulating Agents (ESAs) have become ...
11
Association of anemia and mineral and bone disorder with health-related quality of life in Asian pre-dialysis patients
... Health-related quality of life (HRQoL) has become in- creasingly recognized as an important outcome of med- ical treatment over the past two decades [6]. It is a multi-faceted measure of the impact of diseases on pa- ...
10